Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.59 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | USP14 | P54578 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905864 | 1.00 | HTR2C (0.59) | HTR2CHTR2AHTR2BPTGDR2HTR6 | |
| SCHEMBL906013 | 1.00 | HTR2C (0.59) | HTR2CHTR2AHTR2BPTGDR2HTR6 | |
| Hydrochloric Acid SCHEMBL6025608 | 0.99 | HTR2C (0.58) | HTR2CHTR2AHTR2BPTGDR2HTR6 | |
| Hydrochloric Acid SCHEMBL6025610 | 0.99 | HTR2C (0.58) | HTR2CHTR2AHTR2BPTGDR2HTR6 | |
| Hydrochloric Acid SCHEMBL6025613 | 0.99 | HTR2C (0.58) | HTR2CHTR2AHTR2BPTGDR2HTR6 | |
| SCHEMBL905950 | 0.90 | HTR2C (0.56) | HTR2CHTR2AHTR2BPTGDR2HTR6 | |
| SCHEMBL7151987 | 0.90 | HTR2C (0.56) | HTR2CHTR2AHTR2BPTGDR2HTR6 | |
| SCHEMBL905767 | 0.90 | HTR2C (0.56) | HTR2CHTR2AHTR2BPTGDR2HTR6 | |
| SCHEMBL6025146 | 0.81 | HTR2C (0.39) | HTR2CHTR2APTGDR2HTR6GAA | |
| SCHEMBL10249290 | 0.79 | HTR2C (0.69) | HTR2CHTR2AHTR6GAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1274711-B1 | NEW AZA-INDOLYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | EP | claimed |
| EP-1274711-A1 | NEW AZA-INDOLYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-15 | — | — | EP | claimed |
| WO-2001066548-A1 | NEW AZA-INDOLYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-13 | — | — | WO | claimed |
| EP-1132389-A1 | New aza-indolyl derivatives for the treatment of obesity | VERNALIS RESEARCH LIMITED (GB) | 2001-09-12 | — | — | EP | claimed |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9079907-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| US-9079907-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| EP-2018863-B9 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2015-02-18 | — | — | EP | disclosed |
| EP-2789338-A2 | Condensed pyridine derivate and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-10-15 | — | — | EP | disclosed |
| EP-2018863-B1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2742936-A1 | Fused heterocyclic compound and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-06-18 | — | — | EP | disclosed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| US-6583134-B2 | Tricyclic aza-indolyl derivatives substituted with ethylamine group is useful for treating central nervous system disorder,cardiovascular disorder, gastrointestinal disorders, diabetes insipidus, and particularly useful for obesity | HOFFMAN-LA ROCHE INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1274711-A1 | NEW AZA-INDOLYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-15 | — | — | EP | disclosed |
| US-20010025039-A1 | Aza- indolyl derivatives for treating obesity | HOFFMANN-LA ROCHE INC. | 2001-09-27 | — | — | US | disclosed |
| WO-2001066548-A1 | NEW AZA-INDOLYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-13 | — | — | WO | disclosed |
| EP-1132389-A1 | New aza-indolyl derivatives for the treatment of obesity | VERNALIS RESEARCH LIMITED (GB) | 2001-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025039-A1 | Aza- indolyl derivatives for treating obesity | GPR119, GIPR, INMT | HTR2C 410/4885HTR2A 488/4885HTR2B 470/4885 |
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | HTR2C 1/4885HTR2A 6/4885HTR2B 10/4885 |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | HTR2C 1/4885HTR2A 4/4885HTR2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.